Surface modification of polyurethane using sulfonated PEG grafted polyrotaxane for improved biocompatibility

被引：19

作者：

Park, HD

Bae, JW

Park, KD ^{[1
]}

Ooya, T

Yui, N

Jang, JH

Han, DK

Shin, JW

机构：

[1] Ajou Univ, Dept Mol Sci & Technol, Suwon 443749, South Korea

[2] Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan

[3] Inha Univ, Dept Biochem, Coll Med, Inchon 402751, South Korea

[4] Korea Inst Sci & Technol, Biomat Res Ctr, Seoul 136791, South Korea

[5] Inje Univ, Dept Biomed Engn, Gimhae 621749, South Korea

来源：

MACROMOLECULAR RESEARCH | 2006年 / 14卷 / 01期

关键词：

polyrotaxane; sulforiated polyethylene glycol; anticoagulant activity; protein adsorption; biocompatible;

D O I：

10.1007/BF03219071

中图分类号：

O63 [高分子化学（高聚物）];

学科分类号：

070305 ; 080501 ; 081704 ;

摘要：

Sulfonated poly(ethylene glycol) (PEG-SO3) grafted polyrotaxanes (PRx-PEG-SO3) were prepared in order to utilize the unique properties of PEG-SO3 and the supramolecular structure of PRx, in which PEG-SO3 grafted alpha-cyclodextrins (alpha-CDs) were threaded onto PEG segments in a PEG-b-poly(propylene glycol) (PPG)-b-PEG triblock copolymer (Pluronic) chain capped with bulky end groups. Some of the PRx-PEG-SO3 demonstrated a higher anticoagulant activity in case of PRx-PEG-SO3 (P105), and compared with the control they showed a lower fibrinogen adsorption in PRx-PEG-SO3 (F68) and a higher binding affinity with fibroblast growth factor. The obtained results suggested that polyrotaxane incorporated with PEG-SO3 may be applicable to the surface modification of clinically used polymers, especially for blood/cell compatible medical devices.

引用

页码：73 / 80

页数：8

共 36 条

[11] Vascularization in vivo caused by the controlled release of fibroblast growth factor-2 from an injectable chitosan/non-anticoagulant heparin hydrogel [J].